Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.

Collins KP, Jackson KM, Gustafson DL.

J Pharmacol Exp Ther. 2018 Feb 8. pii: jpet.117.245639. doi: 10.1124/jpet.117.245639. [Epub ahead of print]

2.

Canine sarcomas as a surrogate for the human disease.

Gustafson DL, Duval DL, Regan DP, Thamm DH.

Pharmacol Ther. 2018 Jan 30. pii: S0163-7258(18)30019-6. doi: 10.1016/j.pharmthera.2018.01.012. [Epub ahead of print] Review.

PMID:
29378221
3.

Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus.

Briggs JW, Ren L, Chakrabarti KR, Tsai YC, Weissman AM, Hansen RJ, Gustafson DL, Khan YA, Dinman JD, Khanna C.

PLoS One. 2017 Sep 19;12(9):e0185089. doi: 10.1371/journal.pone.0185089. eCollection 2017.

4.

Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats.

Herndon AK, Quimby JM, Sieberg LG, Davis L, Caress AL, Ligas S, Hansen RJ, Wittenburg LA, Gustafson DL.

J Feline Med Surg. 2017 Sep 1:1098612X17729310. doi: 10.1177/1098612X17729310. [Epub ahead of print]

PMID:
28905667
5.

A Review of Digital, Social, and Mobile Technologies in Health Professional Education.

Curran V, Matthews L, Fleet L, Simmons K, Gustafson DL, Wetsch L.

J Contin Educ Health Prof. 2017 Summer;37(3):195-206. doi: 10.1097/CEH.0000000000000168.

PMID:
28834849
6.

Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide.

Stroda KA, Murphy JD, Hansen RJ, Brownlee L, Atencio EA, Gustafson DL, Lana SE.

Am J Vet Res. 2017 Jul;78(7):862-866. doi: 10.2460/ajvr.78.7.862.

PMID:
28650232
7.

Expression of Phosphorylated KIT in Canine Mast Cell Tumor.

Halsey CHC, Thamm DH, Weishaar KM, Burton JH, Charles JB, Gustafson DL, Avery AC, Ehrhart EJ.

Vet Pathol. 2017 May;54(3):387-394. doi: 10.1177/0300985816688943. Epub 2017 Jan 27.

PMID:
28129097
8.

Assessment of absorption of transdermal ondansetron in normal research cats.

Zajic LB, Herndon AK, Sieberg LG, Caress AL, Morgan PK, Hansen RJ, Wittenburg LA, Gustafson DL, Quimby JM.

J Feline Med Surg. 2017 Dec;19(12):1245-1248. doi: 10.1177/1098612X16688807. Epub 2017 Jan 23.

PMID:
28112563
9.

Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats.

Worley DR, Hansen RJ, Wittenburg LA, Chubb LS, Gustafson DL.

Anticancer Res. 2016 Oct;36(10):5071-5078.

10.

Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study.

Benson KK, Zajic LB, Morgan PK, Brown SR, Hansen RJ, Lunghofer PJ, Wittenburg LA, Gustafson DL, Quimby JM.

J Feline Med Surg. 2017 Oct;19(10):998-1006. doi: 10.1177/1098612X16667168. Epub 2016 Sep 1.

PMID:
27613493
11.

mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo.

Morrow JJ, Mendoza A, Koyen A, Lizardo MM, Ren L, Waybright TJ, Hansen RJ, Gustafson DL, Zhou M, Fan TM, Scacheri PC, Khanna C.

Clin Cancer Res. 2016 Dec 15;22(24):6129-6141. Epub 2016 Jun 24.

12.

Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.

Barnard RA, Regan DP, Hansen RJ, Maycotte P, Thorburn A, Gustafson DL.

J Pharmacol Exp Ther. 2016 Aug;358(2):282-93. doi: 10.1124/jpet.116.233908. Epub 2016 May 26.

13.

Challenging 'girls only' publicly funded human papillomavirus vaccination programmes.

Law VG, Gustafson DL.

Nurs Inq. 2017 Jan;24(1). doi: 10.1111/nin.12140. Epub 2016 May 20.

PMID:
27198909
14.

The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.

Fowles JS, Dailey DD, Gustafson DL, Thamm DH, Duval DL.

Vet Comp Oncol. 2017 Jun;15(2):481-492. doi: 10.1111/vco.12192. Epub 2016 May 19.

15.

A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.

Tabakoff B, Ren W, Vanderlinden L, Snell LD, Matheson CJ, Wang ZJ, Levinson R, Smothers CT, Woodward JJ, Honse Y, Lovinger D, Rush AM, Sather WA, Gustafson DL, Hoffman PL.

Eur J Pharmacol. 2016 Aug 5;784:1-14. doi: 10.1016/j.ejphar.2016.05.006. Epub 2016 May 5.

16.

Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.

Zhou Q, Abraham AD, Li L, Babalmorad A, Bagby S, Arcaroli JJ, Hansen RJ, Valeriote FA, Gustafson DL, Schaack J, Messersmith WA, LaBarbera DV.

Oncogene. 2016 Sep 22;35(38):4990-9. doi: 10.1038/onc.2016.29. Epub 2016 Mar 7.

17.

Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma.

Fowles JS, Brown KC, Hess AM, Duval DL, Gustafson DL.

BMC Bioinformatics. 2016 Feb 19;17:93. doi: 10.1186/s12859-016-0942-8.

18.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review. No abstract available.

PMID:
26843188
19.

Does the public receive and adhere to boil water advisory recommendations? A cross-sectional study in Newfoundland and Labrador, Canada.

Jones-Bitton A, Gustafson DL, Butt K, Majowicz SE.

BMC Public Health. 2016 Jan 5;16:14. doi: 10.1186/s12889-015-2688-z.

20.

Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs.

Larson JC, Allstadt SD, Fan TM, Khanna C, Lunghofer PJ, Hansen RJ, Gustafson DL, Legendre AM, Galyon GD, LeBlanc AK, Martin-Jimenez T.

Am J Vet Res. 2016 Jan;77(1):65-71. doi: 10.2460/ajvr.77.1.65.

21.

Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.

Gustafson DL, Fowles JS, Brown KC, Theodorescu D.

Assay Drug Dev Technol. 2015 Dec;13(10):623-7. doi: 10.1089/adt.2015.29012.dlgdrrr.

22.

Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease.

Fitzpatrick RL, Wittenburg LA, Hansen RJ, Gustafson DL, Quimby JM.

J Vet Pharmacol Ther. 2016 Aug;39(4):350-5. doi: 10.1111/jvp.12286. Epub 2015 Dec 14.

PMID:
26667224
23.

Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus).

Watson MK, Wittenburg LA, Bui CT, Jarosz KA, Gustafson DL, Johnston MS.

Am J Vet Res. 2015 Nov;76(11):946-51. doi: 10.2460/ajvr.76.11.946.

PMID:
26512539
24.

Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at -20°C and room temperature.

Bachtel JC, Pendergraft JS, Rosychuk RA, Gustafson DL, Hansen RJ, Lunghofer PJ.

Vet Dermatol. 2015 Aug;26(4):228-e50. doi: 10.1111/vde.12222.

PMID:
26178603
25.

Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.

Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, Thamm DH, Gustafson DL, Bradner JE, Williams RM.

Cancer Chemother Pharmacol. 2015 Apr;75(4):671-82. doi: 10.1007/s00280-015-2675-1. Epub 2015 Jan 24.

26.

Methodological and ethical issues in research using social media: a metamethod of Human Papillomavirus vaccine studies.

Gustafson DL, Woodworth CF.

BMC Med Res Methodol. 2014 Dec 2;14:127. doi: 10.1186/1471-2288-14-127.

27.

Single- and multiple dose pharmacokinetics and multiple dose pharmacodynamics of oral ABT-116 (a TRPV1 antagonist) in dogs.

Niyom S, Mama KR, Gustafson DL, Rezende ML.

J Vet Pharmacol Ther. 2015 Aug;38(4):336-43. doi: 10.1111/jvp.12180. Epub 2014 Nov 5.

PMID:
25376244
28.

Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats.

Griffenhagen GM, Rezende ML, Gustafson DL, Hansen RJ, Lunghofer PJ, Mama KR.

Vet Anaesth Analg. 2015 Sep;42(5):472-83. doi: 10.1111/vaa.12233. Epub 2014 Oct 20.

PMID:
25327817
29.

Pharmacokinetics of sustained-release analgesics in mice.

Kendall LV, Hansen RJ, Dorsey K, Kang S, Lunghofer PJ, Gustafson DL.

J Am Assoc Lab Anim Sci. 2014 Sep;53(5):478-84.

30.

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH.

Autophagy. 2014 Aug;10(8):1415-25. doi: 10.4161/auto.29165. Epub 2014 May 20.

31.

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH.

BMC Vet Res. 2014 May 6;10:105. doi: 10.1186/1746-6148-10-105.

32.

Ethics, "Vulnerability," and Feminist Participatory Action Research With a Disability Community.

Gustafson DL, Brunger F.

Qual Health Res. 2014 Jul;24(7):997-1005. Epub 2014 May 28.

PMID:
24872327
33.

Anonymous HIV testing: what does it mean in policy and practice? A case study in Newfoundland and Labrador, Canada.

Hancock A, Gustafson DL.

J Assoc Nurses AIDS Care. 2014 Sep-Oct;25(5):436-49. doi: 10.1016/j.jana.2014.01.007. Epub 2014 Apr 20.

PMID:
24759055
34.

STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious.

Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A.

Cancer Res. 2014 May 1;74(9):2579-90. doi: 10.1158/0008-5472.CAN-13-3470. Epub 2014 Mar 3.

35.

Autophagy and cancer therapy.

Thorburn A, Thamm DH, Gustafson DL.

Mol Pharmacol. 2014 Jun;85(6):830-8. doi: 10.1124/mol.114.091850. Epub 2014 Feb 26. Review.

36.

Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats.

Quimby JM, Lake RC, Hansen RJ, Lunghofer PJ, Gustafson DL.

J Vet Pharmacol Ther. 2014 Aug;37(4):348-53. doi: 10.1111/jvp.12094. Epub 2013 Dec 16.

37.

Evaluation of antioxidant capacity and inflammatory cytokine gene expression in horses fed silibinin complexed with phospholipid.

Hackett ES, Mama KR, Twedt DC, Gustafson DL.

Am J Vet Res. 2013 Oct;74(10):1333-9. doi: 10.2460/ajvr.74.10.1333.

PMID:
24066918
38.

Pharmacokinetics and safety of silibinin in horses.

Hackett ES, Mama KR, Twedt DC, Gustafson DL.

Am J Vet Res. 2013 Oct;74(10):1327-32. doi: 10.2460/ajvr.74.10.1327.

PMID:
24066917
39.

Structure-activity relationships for biodistribution, pharmacokinetics, and excretion of atomically precise nanoclusters in a murine model.

Wong OA, Hansen RJ, Ni TW, Heinecke CL, Compel WS, Gustafson DL, Ackerson CJ.

Nanoscale. 2013 Nov 7;5(21):10525-33. doi: 10.1039/c3nr03121g. Epub 2013 Sep 17.

40.

Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.

Hudachek SF, Gustafson DL.

Anticancer Drugs. 2013 Oct;24(9):958-68. doi: 10.1097/CAD.0b013e3283645e1a.

41.

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG.

Clin Cancer Res. 2013 Aug 1;19(15):4149-62. doi: 10.1158/1078-0432.CCR-12-3140. Epub 2013 Jun 11.

42.

A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.

Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Tsai WY, Wu DP, Lee V, Greenlee H.

Integr Cancer Ther. 2014 Jan;13(1):46-53. doi: 10.1177/1534735413490798. Epub 2013 Jun 11.

43.

Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.

Fowles JS, Denton CL, Gustafson DL.

Vet Comp Oncol. 2015 Sep;13(3):288-304. doi: 10.1111/vco.12044. Epub 2013 Jun 7.

PMID:
23745794
44.

Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.

Hudachek SF, Gustafson DL.

J Pharmacokinet Pharmacodyn. 2013 Aug;40(4):437-49. doi: 10.1007/s10928-013-9317-1. Epub 2013 Apr 25.

45.

Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.

Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG.

Front Pharmacol. 2013 Mar 22;4:22. doi: 10.3389/fphar.2013.00022. eCollection 2013.

46.

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.

Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD.

PLoS One. 2013;8(3):e58089. doi: 10.1371/journal.pone.0058089. Epub 2013 Mar 8.

47.

Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease.

De Miranda BR, Miller JA, Hansen RJ, Lunghofer PJ, Safe S, Gustafson DL, Colagiovanni D, Tjalkens RB.

J Pharmacol Exp Ther. 2013 Apr;345(1):125-38. doi: 10.1124/jpet.112.201558. Epub 2013 Jan 14.

48.

Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.

Hudachek SF, Gustafson DL.

J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):157-76. doi: 10.1007/s10928-012-9295-8. Epub 2013 Jan 12.

49.

Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity.

Mitchell LA, Hansen RJ, Beaupre AJ, Gustafson DL, Dow SW.

Int Immunopharmacol. 2013 Feb;15(2):357-63. doi: 10.1016/j.intimp.2012.11.016. Epub 2012 Dec 13.

50.

Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas.

Venable RO, Worley DR, Gustafson DL, Hansen RJ, Ehrhart EJ 3rd, Cai S, Cohen MS, Forrest ML.

Am J Vet Res. 2012 Dec;73(12):1969-76. doi: 10.2460/ajvr.73.12.1969.

Supplemental Content

Loading ...
Support Center